The best indicator for AbbVie (ABBV)
We backtested 20 indicators across daily, weekly and hourly charts on real AbbVie (ABBV) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Breakout
On the daily chart, this is the strongest risk-adjusted edge we found for AbbVie (ABBV) over ~13.4 years — trailing buy-and-hold by 9.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Bollinger Breakout ✓ | Daily | 9.9% | 0.77 | -21.0% | 50.0% | 56 | -9.7% |
| 2 | Holy Grail Confluence ✓ | Daily | 9.9% | 0.73 | -26.2% | 86.4% | 22 | -9.8% |
| 3 | RSI Mean-Reversion ✓ | Daily | 6.6% | 0.69 | -24.5% | 75.0% | 20 | -13.0% |
| 4 | Williams %R ✓ | Weekly | 8.4% | 0.6 | -25.2% | 83.3% | 18 | -11.2% |
| 5 | WaveTrend (8/6/4) ✓ | Daily | 9.3% | 0.57 | -33.0% | 68.8% | 48 | -10.3% |
| 6 | Donchian Breakout ✓ | Daily | 8.1% | 0.55 | -25.8% | 45.5% | 55 | -11.6% |
| 7 | EMA-10 Trend ✓ | Weekly | 8.8% | 0.55 | -42.0% | 42.6% | 68 | -10.9% |
| 8 | Stochastic ✓ | Daily | 7.0% | 0.51 | -29.7% | 70.5% | 61 | -12.6% |
| 9 | WaveTrend (8/6/4) ✓ | Weekly | 10.0% | 0.69 | -35.4% | 90.9% | 11 | -9.7% |
| 10 | RSI Trend (>50) ✓ | Daily | 7.5% | 0.48 | -43.0% | 35.8% | 176 | -12.1% |
| 11 | Williams %R ✓ | Daily | 6.8% | 0.47 | -29.7% | 69.5% | 82 | -12.9% |
| 12 | Bollinger Mean-Reversion ✓ | Daily | 5.6% | 0.46 | -25.1% | 66.7% | 51 | -14.0% |
| 13 | Rate of Change ✓ | Daily | 6.6% | 0.44 | -46.5% | 40.1% | 197 | -13.0% |
| 14 | ADX / DMI ✓ | Daily | 5.5% | 0.43 | -40.6% | 40.2% | 97 | -14.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For AbbVie (ABBV), Bollinger Breakout on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.